Drug:
Reaction: THERAPY INTERRUPTED
20260101 - 20261231
No. 301 - 400
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 301 | 26906227 |
CO |
54 | 1 |
Thrombocytopenia, Therapy interrupted, |
||||
ROMIPLOSTIM, |
||||
| 302 | 26906495 |
US |
74 | 1 |
Drug effect less than expected, Therapy interrupted, |
||||
VIBEGRON, |
||||
| 303 | 26906583 |
US |
78 | 1 |
Product dispensing issue, Therapy interrupted, |
||||
LENALIDOMIDE, |
||||
| 304 | 26906940 |
US |
87 | 1 |
Fatigue, Therapy interrupted, |
||||
RELUGOLIX, RELUGOLIX, |
||||
| 305 | 26907425 |
US |
30 | 1 |
Ankylosing spondylitis, Axial spondyloarthritis, HLA-B*27 positive, Chest pain, Therapy interrupted, Intervertebral disc protrusion, Blood pressure increased, Overweight, Palpitations, Pain, Polycythaemia, Exercise tolerance decreased, |
||||
ETANERCEPT, ETANERCEPT, ETANERCEPT, ETANERCEPT, ETANERCEPT, ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE, ACETAMINOPHEN, MELOXICAM, GABAPENTIN, IBUPROFEN SODIUM, IBUPROFEN, IBUPROFEN TABLETS, COATED, |
||||
| 306 | 26907465 |
US |
2 | |
Nephrolithiasis, Psoriatic arthropathy, Surgery, Therapy interrupted, |
||||
ETANERCEPT, ETANERCEPT, ETANERCEPT, |
||||
| 307 | 26907500 |
US |
42 | |
Therapy interrupted, Product preparation issue, |
||||
ABATACEPT, |
||||
| 308 | 26907513 |
US |
2 | |
Multiple sclerosis, Emotional distress, Intentional product misuse, Product dispensing error, Therapy interrupted, Product availability issue, |
||||
GLATIRAMER ACETATE, GLATIRAMER ACETATE INJECTION, GLATIRAMER, GLATIRAMER ACETATE, GLATIRAMER ACETATE INJECTION, GLATIRAMER, GLATIRAMER ACETATE, GLATIRAMER ACETATE INJECTION, GLATIRAMER, GLATIRAMER ACETATE, GLATIRAMER ACETATE INJECTION, GLATIRAMER, GLATIRAMER ACETATE, GLATIRAMER ACETATE INJECTION, GLATIRAMER, GLATIRAMER ACETATE, GLATIRAMER ACETATE INJECTION, GLATIRAMER, GLATIRAMER ACETATE, GLATIRAMER ACETATE INJECTION, GLATIRAMER, GLATIRAMER ACETATE, GLATIRAMER ACETATE INJECTION, GLATIRAMER, |
||||
| 309 | 26908227 |
US |
76 | |
Dehydration, Inability to afford medication, Therapy interrupted, |
||||
| 310 | 26908411 |
EU |
2 | |
Device delivery system issue, Therapy interrupted, Device safety feature issue, |
||||
ABATACEPT, |
||||
| 311 | 26908447 |
US |
1 | |
Ankylosing spondylitis, Weight increased, Therapy interrupted, Onychomadesis, Insurance issue, |
||||
CERTOLIZUMAB PEGOL, ALBUTEROL SULFATE, MELOXICAM, BUDESONIDE AND FORMOTEROL FUMARATE DIHYDRATE, |
||||
| 312 | 26909009 |
US |
51 | 1 |
Hospitalisation, Therapy interrupted, |
||||
RIFAXIMIN, |
||||
| 313 | 26909022 |
US |
74 | 2 |
Pancreatic carcinoma, Therapy interrupted, |
||||
RIFAXIMIN, RIFAXIMIN, |
||||
| 314 | 26909353 |
US |
65 | 2 |
Rheumatoid arthritis, Therapy interrupted, Insurance issue, |
||||
CERTOLIZUMAB PEGOL, ABALOPARATIDE, |
||||
| 315 | 26911895 |
|||
Drug intolerance, Sleep disorder, Asthenia, Affective disorder, Therapy interrupted, |
||||
ARIPIPRAZOLE ORALLY DISINTEGRATING, ARIPIPRAZOLE, ARIPIPRAZOLE ORAL, |
||||
| 316 | 26912197 |
1 | ||
Poor peripheral circulation, Therapy interrupted, Leg amputation, |
||||
APALUTAMIDE, |
||||
| 317 | 26912521 |
45 | 1 | |
Bradycardia, Cardiac arrest, Atrioventricular node dysfunction, Therapy interrupted, |
||||
METOCLOPRAMIDE, METOCLOPRAMIDE HYDROCHLORIDE, |
||||
| 318 | 26912665 |
83 | 2 | |
Therapy interrupted, |
||||
AVACOPAN, |
||||
| 319 | 26912735 |
79 | 2 | |
Therapy interrupted, |
||||
AVACOPAN, |
||||
| 320 | 26912824 |
2 | ||
Hospitalisation, Product use issue, Therapy interrupted, |
||||
VIGABATRIN, VIGABATRIN, FAMOTIDINE, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, RIVAROXABAN, ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE, ACETAMINOPHEN, |
||||
| 321 | 26912969 |
74 | 1 | |
Rhinovirus infection, Histoplasmosis, Therapy interrupted, |
||||
MYCOPHENOLIC ACID, MYCOPHENILIC ACID, EMPAGLIFLOZIN, SERTRALINE, IRBESARTAN, ATORVASTATIN CALCIUM, CARVEDILOL, INSULIN GLARGINE, NIFEDIPINE, INSULIN ASPART, PANTOPRAZOLE SODIUM, TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, |
||||
| 322 | 26918717 |
82 | 2 | |
Therapy interrupted, Sinusitis, Pneumonia, |
||||
MAVACAMTEN, |
||||
| 323 | 26918724 |
53 | 2 | |
Endocarditis staphylococcal, Mitral valve replacement, Therapy interrupted, |
||||
MAVACAMTEN, |
||||
| 324 | 26918818 |
78 | 2 | |
Sepsis, Therapy interrupted, |
||||
UPADACITINIB, |
||||
| 325 | 26918847 |
54 | 2 | |
Intestinal obstruction, Therapy interrupted, |
||||
UPADACITINIB, |
||||
| 326 | 26918859 |
56 | 2 | |
Spinal operation, Therapy interrupted, |
||||
IXEKIZUMAB, |
||||
| 327 | 26904162 |
US |
65 | 2 |
Therapy interrupted, Low density lipoprotein increased, Device difficult to use, Drug dose omission by device, |
||||
EVOLOCUMAB, |
||||
| 328 | 26904184 |
CA |
1 | |
Suicidal ideation, Pain, Psoriatic arthropathy, Therapy interrupted, Herpes zoster, |
||||
CERTOLIZUMAB PEGOL, |
||||
| 329 | 26904501 |
US |
59 | 1 |
Product distribution issue, Therapy interrupted, |
||||
LENALIDOMIDE, |
||||
| 330 | 26918237 |
69 | 1 | |
Therapy interrupted, Fall, Joint injury, Neck injury, |
||||
TAFAMIDIS, |
||||
| 331 | 26918286 |
71 | 1 | |
Sepsis, Therapy interrupted, |
||||
GUSELKUMAB, |
||||
| 332 | 26902885 |
CA |
39 | |
Scar, Pneumonia, Epistaxis, Abdominal pain, Therapy interrupted, Off label use, Product dose omission issue, Underdose, |
||||
INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, |
||||
| 333 | 26903141 |
US |
56 | |
Eructation, Fatigue, Myalgia, Abdominal discomfort, Diarrhoea, Abdominal pain upper, Nausea, Vomiting, Constipation, Pruritus, Therapy interrupted, |
||||
RESMETIROM, RESMETIROM, LISINOPRIL, CETIRIZINE HYDROCHLORIDE, ICOSAPENT ETHYL, |
||||
| 334 | 26903235 |
US |
||
Weight decreased, Weight increased, Therapy interrupted, |
||||
RESMETIROM, |
||||
| 335 | 26903341 |
CA |
25 | |
Condition aggravated, Weight decreased, Weight increased, Therapeutic response shortened, Therapy interrupted, Off label use, Product dose omission issue, Inappropriate schedule of product administration, Suspected off label use, |
||||
INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, |
||||
| 336 | 26903449 |
US |
59 | 1 |
Psoriasis, Therapy interrupted, Product use issue, Insurance issue, |
||||
BIMEKIZUMAB, |
||||
| 337 | 26903487 |
US |
71 | 2 |
Neuroleptic malignant syndrome, Product storage error, Therapy interrupted, General symptom, |
||||
FOSCARBIDOPA/FOSLEVODOPA, |
||||
| 338 | 26897586 |
US |
58 | 2 |
Stress fracture, Product prescribing issue, Therapy interrupted, |
||||
LENALIDOMIDE, |
||||
| 339 | 26897698 |
CA |
58 | |
Haematochezia, Blister, Condition aggravated, Product availability issue, Inappropriate schedule of product administration, Off label use, Product dose omission issue, Therapy interrupted, Overdose, |
||||
INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, |
||||
| 340 | 26898123 |
US |
74 | 2 |
Product supply issue, Therapy interrupted, |
||||
POMALIDOMIDE, |
||||
| 341 | 26898131 |
CO |
52 | 2 |
Finger deformity, Joint stiffness, Product dispensing issue, Therapy interrupted, Pain, Off label use, Erythema, Inflammation, |
||||
CERTOLIZUMAB PEGOL, CERTOLIZUMAB PEGOL, CERTOLIZUMAB PEGOL, |
||||
| 342 | 26898343 |
US |
2 | |
Joint stiffness, Therapy interrupted, |
||||
CERTOLIZUMAB PEGOL, CERTOLIZUMAB PEGOL, |
||||
| 343 | 26898502 |
US |
80 | |
Urinary tract infection, Acute kidney injury, Therapy interrupted, Mobility decreased, |
||||
MITOMYCIN, MITOMYCIN, MITOMYCIN, MITOMYCIN, MITOMYCIN, |
||||
| 344 | 26898504 |
US |
||
Foot fracture, Therapy interrupted, |
||||
DENOSUMAB, |
||||
| 345 | 26898526 |
US |
2 | |
Surgery, Post procedural pneumonia, Therapy interrupted, |
||||
BRENSOCATIB, CALCIUM CARBONATE, ANTACID, CIMETIDINE, DICYCLOMINE HYDROCHLORIDE, ESOMEPRAZOLE, ESOMEPRAZOLE MAGNESIUM, LEVALBUTEROL, LEVALBUTEROL HYDROCHLORIDE, MAGNESIUM OXIDE, MONTELUKAST, SERTRALINE, ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE, ACETAMINOPHEN, ERGOCALCIFEROL, ZINC CHLORIDE, |
||||
| 346 | 26898897 |
US |
77 | 1 |
Suicidal ideation, Pneumonia fungal, Therapy interrupted, Dehydration, Injection site bruising, Homicidal ideation, Therapeutic procedure, Cough, Wrong technique in product usage process, Product availability issue, Myasthenia gravis, Depression, Fatigue, |
||||
BIMEKIZUMAB, BIMEKIZUMAB, |
||||
| 347 | 26898922 |
US |
71 | 2 |
Product distribution issue, Therapy interrupted, |
||||
POMALIDOMIDE, |
||||
| 348 | 26899150 |
US |
19 | |
Product use issue, Therapy interrupted, |
||||
ISOTRETINOIN, ISOTRETINOIN, |
||||
| 349 | 26899197 |
US |
2 | |
Hospitalisation, Aphonia, Therapy interrupted, |
||||
AMIKACIN, FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, LORAZEPAM, CALCIUM, ERGOCALCIFEROL, SODIUM CHLORIDE, SODIUM CHLORIDE TABLET, SODIUM CHLORIDE TABLETS, MIRTAZAPINE, PIROXICAM, |
||||
| 350 | 26899208 |
US |
66 | 2 |
Product distribution issue, Therapy interrupted, |
||||
LENALIDOMIDE, |
||||
| 351 | 26899297 |
GB |
1 | |
Localised infection, Intentional dose omission, Therapy interrupted, Product prescribing issue, Illness, |
||||
CERTOLIZUMAB PEGOL, |
||||
| 352 | 26899585 |
US |
79 | 1 |
Product distribution issue, Therapy interrupted, |
||||
LENALIDOMIDE, |
||||
| 353 | 26899798 |
US |
85 | 1 |
Drug ineffective, Therapy interrupted, |
||||
VIBEGRON, |
||||
| 354 | 26899950 |
US |
36 | 1 |
Migraine, Therapy interrupted, |
||||
ERENUMAB-AOOE, |
||||
| 355 | 26900023 |
US |
1 | |
Therapy interrupted, |
||||
TILDRAKIZUMAB-ASMN, |
||||
| 356 | 26900505 |
US |
0 | 2 |
Insomnia, Middle insomnia, Therapy interrupted, |
||||
PROPRANOLOL HYDROCHLORIDE, |
||||
| 357 | 26900651 |
US |
2 | |
Migraine, Therapy interrupted, |
||||
ERENUMAB-AOOE, |
||||
| 358 | 26901123 |
US |
0 | 2 |
Therapy interrupted, Inappropriate schedule of product administration, Off label use, |
||||
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE, |
||||
| 359 | 26901145 |
US |
2 | |
Therapy interrupted, |
||||
PROPRANOLOL HYDROCHLORIDE, |
||||
| 360 | 26901540 |
US |
60 | 1 |
Product distribution issue, Therapy interrupted, |
||||
LENALIDOMIDE, |
||||
| 361 | 26901642 |
US |
2 | |
Therapy interrupted, |
||||
PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE, PROPRANOLOL HYDROCHLORIDE, |
||||
| 362 | 26902115 |
US |
66 | 2 |
Product distribution issue, Therapy interrupted, |
||||
MAVACAMTEN, |
||||
| 363 | 26902255 |
US |
2 | |
Hepatic cirrhosis, Therapy interrupted, |
||||
APREMILAST, |
||||
| 364 | 26908201 |
2 | ||
Laboratory test abnormal, Therapy interrupted, |
||||
RIBOCICLIB, ANASTROZOLE, ANASTROZOLE TABLETS, PANTOPRAZOLE SODIUM, SELADELPAR LYSINE, SIMVASTATIN, OXYCODONE HYDROCHLORIDE AND ACETAMINOPHEN, DENOSUMAB, SERTRALINE HYDROCHLORIDE, URSODIOL, URSOSIOL, METOCLOPRAMIDE HYDROCHLORIDE, |
||||
| 365 | 26908323 |
48 | 2 | |
Hospitalisation, Therapy interrupted, |
||||
AVACOPAN, |
||||
| 366 | 26908327 |
73 | 1 | |
Dialysis, Therapy interrupted, Rehabilitation therapy, Infection, |
||||
AVACOPAN, |
||||
| 367 | 26908440 |
38 | 2 | |
Somnolence, Therapy interrupted, |
||||
ZURANOLONE, |
||||
| 368 | 26912989 |
69 | 1 | |
Spinal disorder, Condition aggravated, Therapy interrupted, Insurance issue, |
||||
ADALIMUMAB-AATY, |
||||
| 369 | 26913545 |
58 | 2 | |
Clostridium difficile infection, Nocturia, Therapy interrupted, |
||||
ABALOPARATIDE, |
||||
| 370 | 26913553 |
69 | 2 | |
Therapy interrupted, |
||||
ABALOPARATIDE, |
||||
| 371 | 26913621 |
1 | ||
Therapy interrupted, Haemarthrosis, |
||||
EMICIZUMAB, |
||||
| 372 | 26913663 |
1 | ||
Crohn^s disease, Insurance issue, Therapy interrupted, |
||||
| 373 | 26913684 |
1 | ||
Therapy interrupted, Dyspnoea, |
||||
MACITENTAN, SOTATERCEPT-CSRK, SELEXIPAG, RIOCIGUAT, |
||||
| 374 | 26891976 |
US |
71 | 2 |
Product prescribing issue, Therapy interrupted, |
||||
LENALIDOMIDE, |
||||
| 375 | 26891977 |
US |
61 | 2 |
Insurance issue, Therapy interrupted, |
||||
LENALIDOMIDE, |
||||
| 376 | 26892010 |
US |
55 | 2 |
Insurance issue, Rheumatoid arthritis, Therapy interrupted, |
||||
ABATACEPT, |
||||
| 377 | 26892030 |
US |
56 | 2 |
Rheumatoid arthritis, Therapy interrupted, |
||||
ETANERCEPT, |
||||
| 378 | 26892157 |
US |
2 | |
Road traffic accident, Headache, Hypertension, Neck pain, Therapy interrupted, Hypoaesthesia, Off label use, |
||||
ERENUMAB-AOOE, ERENUMAB-AOOE, |
||||
| 379 | 26892199 |
US |
2 | |
Drug ineffective, Disturbance in attention, Irritability, Tachycardia, Feeling abnormal, Agitation, Condition aggravated, Sleep disorder, Emotional distress, Therapy interrupted, |
||||
LISDEXAMFETAMINE, |
||||
| 380 | 26892784 |
US |
2 | |
Lung disorder, Nasopharyngitis, Therapy interrupted, |
||||
BRENSOCATIB, ALBUTEROL SULFATE, ALBUTEROL, METHYLPREDNISOLONE ACETATE, GUAIFENESIN, ONDANSETRON HYDROCHLORIDE, ONDANSETRON, ONDANSETRON TABLETS, OMEPRAZOLE MAGNESIUM, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, SERTRALINE, TOBRAMYCIN, TOBRAMYCIN SOLUTION, TOBRAMYCIN SULFATE, |
||||
| 381 | 26893303 |
EU |
71 | 2 |
Pyelonephritis, Acute kidney injury, Renal impairment, Glomerular filtration rate decreased, Therapy interrupted, Hypotension, |
||||
DAPAGLIFLOZIN, DAPAGLIFLOZIN, |
||||
| 382 | 26893589 |
US |
61 | 2 |
Spinal fracture, Pelvic fracture, Fractured coccyx, Fall, Therapy interrupted, |
||||
DENOSUMAB, |
||||
| 383 | 26893634 |
CA |
28 | |
Colitis ulcerative, Accident, Pharyngitis streptococcal, Intentional dose omission, Overdose, Suspected off label use, Inappropriate schedule of product administration, Therapy interrupted, |
||||
INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, INFLIXIMAB-DYYB, VORTIOXETINE, |
||||
| 384 | 26894208 |
JP |
89 | |
Femoral neck fracture, Therapy interrupted, Fall, |
||||
ROMOSOZUMAB-AQQG, |
||||
| 385 | 26894425 |
CA |
2 | |
Pneumonia, Arthralgia, Fatigue, Somnolence, Off label use, Therapy interrupted, |
||||
CANDESARTAN, LORAZEPAM, LEVOTHYROXINE SODIUM, |
||||
| 386 | 26894651 |
1 | ||
Product use issue, Therapy interrupted, Insurance issue, |
||||
| 387 | 26894677 |
1 | ||
Therapy interrupted, |
||||
| 388 | 26894702 |
US |
57 | 2 |
Discomfort, Product use issue, Therapy interrupted, Condition aggravated, |
||||
PROGESTERONE, ESTRADIOL, FOLLICULINUM, OOPHORINUM (SUIS), |
||||
| 389 | 26894720 |
2 | ||
Product use issue, Therapy interrupted, Inadequate housing, Product distribution issue, |
||||
SUCROFERRIC OXYHYDROXIDE, |
||||
| 390 | 26894787 |
2 | ||
Blood pressure decreased, Therapy interrupted, |
||||
| 391 | 26894890 |
31 | 2 | |
Product use issue, Insurance issue, Therapy interrupted, |
||||
ACETAMINOPHEN, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, CALCITRIOL, CALCITRIOL CAPSULES 0.25 MCG, CALCITRIOL CAPSULES 0.5 MCG, CALCIUM ACETATE, CYCLOBENZAPRINE, FERRIC CITRATE, FOLIC ACID, LABETALOL, INSULIN GLARGINE, LOSARTAN, NIFEDIPINE, INSULIN ASPART, ONDANSETRON HYDROCHLORIDE, ONDANSETRON, ONDANSETRON TABLETS, |
||||
| 392 | 26895524 |
US |
13 | 1 |
Pain, Therapy interrupted, |
||||
ADALIMUMAB-ADAZ, ADALIMUMAB-ADAZ, ADALIMUMAB-ADAZ, |
||||
| 393 | 26895539 |
EU |
1 | |
Diabetes mellitus, Dizziness, Therapy interrupted, |
||||
DAROLUTAMIDE, DAROLUTAMIDE, |
||||
| 394 | 26895590 |
US |
1 | |
Chronic kidney disease, Palliative care, Arthritis, Acute kidney injury, Thrombocytopenia, Ileus paralytic, Type 2 diabetes mellitus, Interstitial lung disease, Osteoarthritis, Therapy interrupted, Psoriasis, Carpal tunnel syndrome, Hypertriglyceridaemia, COVID-19, Gout, Hypertension, Obesity, Electrolyte imbalance, |
||||
APREMILAST, ORAL SEMAGLUTIDE, FEBUXOSTAT, BUDESONIDE, GLYCOPYRROLATE, AND FORMOTEROL FUMARATE, DOXAZOSIN MESYLATE, DOXAZOSIN, ESCITALOPRAM, ALBUTEROL SULFATE, SILDENAFIL CITRATE, AMLODIPINE BESYLATE, MONTELUKAST SODIUM, POTASSIUM CHLORIDE, VALSARTAN AND HYDROCHLOROTHIAZIDE, |
||||
| 395 | 26895969 |
US |
79 | 2 |
Therapy interrupted, |
||||
TRIFLURIDINE AND TIPIRACIL, |
||||
| 396 | 26896433 |
US |
2 | |
Rheumatoid arthritis, Therapy interrupted, Insurance issue, Off label use, |
||||
CERTOLIZUMAB PEGOL, CERTOLIZUMAB PEGOL, CERTOLIZUMAB PEGOL, |
||||
| 397 | 26896679 |
EU |
67 | 2 |
Myocardial infarction, Therapy interrupted, |
||||
BRODALUMAB, |
||||
| 398 | 26896744 |
64 | 2 | |
Hyperkalaemia, Therapy interrupted, Blood creatinine increased, |
||||
POTASSIUM CHLORIDE, POTASSIUM CHLORIDE EXTENDED-RELEASE, POTASSIUM CHLORIDE, DEXTROSE MONOHYDRATE, POTASSIUM CHLORIDE ORAL, POTASSIUM CHLORIDE, POTASSIUM CHLORIDE EXTENDED-RELEASE, POTASSIUM CHLORIDE, DEXTROSE MONOHYDRATE, POTASSIUM CHLORIDE ORAL, POTASSIUM CHLORIDE, POTASSIUM CHLORIDE EXTENDED-RELEASE, POTASSIUM CHLORIDE, DEXTROSE MONOHYDRATE, POTASSIUM CHLORIDE ORAL, ACETAMINOPHEN, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, BUPRENORPHINE HYDROCHLORIDE, NALOXONE HYDROCHLORIDE, ESCITALOPRAM, ESCITALOPRAM OXALATE, ESCITSLOPRAM, FUROSEMIDE, LISINOPRIL, METOPROLOL SUCCINATE, METOPROLOL SUCCINATE ER TABLETS, PANTOPRAZOLE, SPIRONOLACTONE, TIRZEPATIDE, |
||||
| 399 | 26897085 |
CA |
55 | 2 |
Upper limb fracture, Therapy interrupted, |
||||
AVACOPAN, |
||||
| 400 | 26897210 |
US |
2 | |
Autoimmune disorder, Rheumatoid arthritis, Therapy interrupted, |
||||
ETANERCEPT, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2026-07-30